Fortress Biotech Increases Stake in Avenue Therapeutics to 13.4% via Annual Equity Grant

summarizeSummary

Fortress Biotech, Inc. increased its beneficial ownership in Avenue Therapeutics to 13.4% following an annual equity grant, a routine event under a Founders Agreement.

check_boxKey Events

• Beneficial Ownership Increase

  Fortress Biotech, Inc. increased its beneficial ownership in Avenue Therapeutics, Inc. to 13.4% of the outstanding common stock.

• Annual Equity Grant

  The increase resulted from an annual equity grant of 111,209 shares of common stock to Fortress Biotech, Inc. under a pre-existing Founders Agreement, valued at approximately $68,948.

• Controlling Shareholder Status

  Fortress Biotech, Inc. also holds all outstanding Class A preferred stock, which provides a voting majority and is convertible into common stock, indicating a controlling interest in the company.

auto_awesomeAnalysis

Fortress Biotech, Inc., a significant and controlling shareholder of Avenue Therapeutics, Inc., has increased its beneficial ownership to 13.4% through an annual equity grant. This grant of 111,209 common shares, valued at approximately $68,948, represents a substantial issuance relative to the company's small market capitalization. While dilutive to existing common shareholders, this transaction is part of a pre-existing Founders Agreement and reflects Fortress Biotech's ongoing, structured involvement and controlling interest in Avenue Therapeutics.